Comparing technology and regulatory landscape of probiotics as food, dietary supplements and live biotherapeutics
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Application of beneficial microorganisms as probiotics targets a broad range of intended uses, from maintaining health and supporting normal bodily functions to curing and preventing diseases. Currently, three main regulatory fields of probiotic products can be defined depending on their intended use: the more similar probiotic foods and probiotic dietary supplements, and live biotherapeutic products. However, it is not always straightforward to classify a probiotic product into one of these categories. The regulatory nuances of developing, manufacturing, investigating and applying each category of probiotic products are not universal, and not always apparent to those unfamiliar with the various global probiotic regulatory guidelines. Various global markets can be significantly different regarding legislation, possible claims, market value and quality requirements for the development and commercialization of probiotic products. Furthermore, different probiotic product categories are also linked with variable costs at different stages of product development. This review outlines the current landscape comparing probiotic foods, probiotic dietary supplements, and live biotherapeutics as probiotic products from a regulatory lens, focusing on product development, manufacturing and production, and clinical research agenda. The aim is to inform and promote a better understanding among stakeholders by outlining the expectations and performance for each probiotic product category, depending on their intended use and targeted geographical region.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The European Union lacks dedicated probiotic legislation, though health claims are regulated. Japan, Brazil, and Canada offer more structured frameworks that mandate safety and efficacy evidence.39”
From Safety and efficacy concerns in Indian probiotics: Insights from whole-genome sequencing and in vitro assessment (2026) · cites this paper as [39]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Probiotics marketed as foods or dietary supplements are subject to food and consumer product safety legislation. In contrast, live biotherapeutic products, intended to treat or prevent diseases, are regulated as biological medicinal products. This means that they must undergo rigorous safety, efficacy, and quality testing similar to that applied to pharmaceuticals [29,30].”
From Current Concepts in Probiotic Safety and Efficacy (2026) · cites this paper as [29]
The cited source says what the claim attributes to it.
In the citing paper
“Regulatory challenges affecting the commercialization of probiotics include the lack of harmonization of regulatory requirements, which can vary by region (e.g., as with drugs or dietary supplements), leading to confusion in interpreting requirements. Efficacy and safety standards also vary, increasing costs and complicating worldwide regulatory compliance, which in turn leads to differences in”
From Current Concepts in Probiotic Safety and Efficacy (2026) · cites this paper as [29]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hill (2014) · doi:10.1038/nrgastro.2014.66 · Cited by 9,592
Innovation in the pharmaceutical industry: New estimates of R&D costs
DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016) · Journal of Health Economics · doi:10.1016/j.jhealeco.2016.01.012 · Cited by 3,359 · cited 1×
“…from synthesis to clinical testing) for drugs is expensive and time-consuming, as it has been reported to average a considerable 31.7 months with inferred out-of-pocket costs of 430 million USD based on 1990– 2013 data on 106 new drugs from 10 biopharmaceutical companies (DiMasi et al., 2016).”
BackgroundInfluentialZheng, J., Wittouck, S., Salvetti, E., Franz, C. M. A. P., Harris, H. M. B., Mattarelli, P., O’Toole, P. W., Pot, B., Vandamme, P., Walter, J., et al. (2020) · International Journal of Systematic and Evolutionary Microbiology · doi:10.1099/ijsem.0.004107 · Cited by 3,313
Clinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536
Better Reporting of Harms in Randomized Trials: An Extension of the CONSORT Statement
Ioannidis, J. P. A., Evans, S. J. W., Gøtzsche, P. C., O'Neill, R. T., Altman, D. G., Schulz, K., Moher, D., & for the CONSORT Group* (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00009 · Cited by 1,593
Marco, M. L., Sanders, M. E., Gänzle, M., Arrieta, M. C., Cotter, P. D., De Vuyst, L., Hill, C., Holzapfel, W., Lebeer, S., Merenstein, D., et al. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00390-5 · Cited by 937
Probiotics for preventing acute upper respiratory tract infections
Hao, Q., Dong, B. R., & Wu, T. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006895.pub3 · Cited by 569
Criteria to Qualify Microorganisms as “Probiotic” in Foods and Dietary Supplements
Binda, S., Hill, C., Johansen, E., Obis, D., Pot, B., Sanders, M. E., Tremblay, A., & Ouwehand, A. C. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.01662 · Cited by 519
Self-citationEmerging issues in probiotic safety: 2023 perspectives
Merenstein, D., Pot, B., Leyer, G., Ouwehand, A. C., Preidis, G. A., Elkins, C. A., Hill, C., Lewis, Z. T., Shane, A. L., Zmora, N., et al. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2185034 · Cited by 481
Self-citationThe Production and Delivery of Probiotics: A Review of a Practical Approach
Fenster, K., Freeburg, B., Hollard, C., Wong, C., Rønhave Laursen, R., & Ouwehand, A. C. (2019) · Microorganisms · doi:10.3390/microorganisms7030083 · Cited by 405
Self-citationFDA no longer has to require animal testing for new drugs
Wadman, M. (2023) · Science · doi:10.1126/science.adg6276 · Cited by 366 · cited 1×
“Recently the FDA can promote a drug or biologic to human trials after either animal or non-animal tests (Wadman, 2023).”
BackgroundLive biotherapeutic products: The importance of a defined regulatory framework
Cordaillat-Simmons, M., Rouanet, A., & Pot, B. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0437-6 · Cited by 328
Identification of probiotic effector molecules: present state and future perspectives
Lebeer, S., Bron, P. A., Marco, M. L., Van Pijkeren, J.-P., O’Connell Motherway, M., Hill, C., Pot, B., Roos, S., & Klaenhammer, T. (2018) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2017.10.007 · Cited by 295
Review article: the future of microbiome‐based therapeutics
Gulliver, E. L., Young, R. B., Chonwerawong, M., D'Adamo, G. L., Thomason, T., Widdop, J. T., Rutten, E. L., Rossetto Marcelino, V., Bryant, R. V., Costello, S. P., et al. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17049 · Cited by 180
Goodman, C., Keating, G., Georgousopoulou, E., Hespe, C., & Levett, K. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-043054 · Cited by 163
EFSA Panel on Dietetic Products, N. A. A. (. (2010) · EFSA Journal · doi:10.2903/j.efsa.2010.1763 · Cited by 162
Postbiotics — when simplification fails to clarify
Aguilar-Toalá, J. E., Arioli, S., Behare, P. V., Belzer, C., Canani, R. B., Chatel, J., D’Auria, E., Freitas, M. Q., Elinav, E., Esmerino, E. A., et al. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00521-6 · Cited by 148
Self-citationConsiderations for determining safety of probiotics: A USP perspective
Roe, A. L., Boyte, M.-E., Elkins, C. A., Goldman, V. S., Heimbach, J., Madden, E., Oketch-Rabah, H., Sanders, M. E., Sirois, J., & Smith, A. (2022) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2022.105266 · Cited by 136
Probiotic use in at-risk populations
Sanders, M. E., Merenstein, D. J., Ouwehand, A. C., Reid, G., Salminen, S., Cabana, M. D., Paraskevakos, G., & Leyer, G. (2016) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2016.07.001 · Cited by 129 · cited 1×
“In healthy subjects probiotic consumption, whether as PF, PDS or LBP, generally does not lead to changes in the fecal microbiota composition, although this may be different for patients (Sanders, 2016).”
BackgroundSelf-citationEFSA Panel on Dietetic Products, N. A. A. (. (2016) · EFSA Journal · doi:10.2903/j.efsa.2016.4369 · Cited by 122
Live Biotherapeutic Products, A Road Map for Safety Assessment
Rouanet, A., Bolca, S., Bru, A., Claes, I., Cvejic, H., Girgis, H., Harper, A., Lavergne, S. N., Mathys, S., Pane, M., et al. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00237 · Cited by 120
Self-citationGlobal analysis of clinical trials with probiotics
Dronkers, T. M. G., Ouwehand, A. C., & Rijkers, G. T. (2020) · Heliyon · doi:10.1016/j.heliyon.2020.e04467 · Cited by 119
Self-citationProbiotics from an industrial perspective
Forssten, S. D., Sindelar, C. W., & Ouwehand, A. C. (2011) · Anaerobe · doi:10.1016/j.anaerobe.2011.04.014 · Cited by 112
Self-citationApplying probiotics and prebiotics in new delivery formats – is the clinical evidence transferable?
Cunningham, M., Vinderola, G., Charalampopoulos, D., Lebeer, S., Sanders, M. E., & Grimaldi, R. (2021) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2021.04.009 · Cited by 93
Shane, A. L., Cabana, M. D., Ellis, C. L., Heimbach, J. T., Hempel, S., Hummelen, R., Lynch, S., Merenstein, D. J., Sanders, M. E., Tancredi, D. J., et al. (2010) · Gut Microbes · doi:10.4161/gmic.1.4.12707 · Cited by 91
Mattia, A., & Merker, R. (2008) · Clinical Infectious Diseases · doi:10.1086/523329 · Cited by 86
Zeilstra, D., Younes, J. A., Brummer, R. J., & Kleerebezem, M. (2018) · Advances in Nutrition · doi:10.1093/advances/nmy046 · Cited by 74
Kleerebezem, M., Binda, S., Bron, P. A., Gross, G., Hill, C., van Hylckama Vlieg, J. E., Lebeer, S., Satokari, R., & Ouwehand, A. C. (2019) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2018.09.007 · Cited by 72
Self-citationProbiotics and microbiota composition
Sanders, M. E. (2016) · BMC Medicine · doi:10.1186/s12916-016-0629-z · Cited by 69 · cited 9×
“Appropriate new clinical outcome measures/biomarkers specifically affected by probiotics are not always known, which can hamper probiotic claims, for example in relation to (immune) defenses against pathogens or support of normal bodily functions (EFSA Panel on Dietetic Products, Nutrition and Allergies, 2016).”
BackgroundResultInfluentialUpdated list of QPS-recommended microorganisms for safety risk assessments carried out by EFSA
Ricci, A., Allende, A., Declan, B., Marianne, C., Davies, R., Gironés, R., Koutsoumanis, K., Lindqvist, R., Nørrung, B., Robertson, L., et al. (2018) · Figshare · doi:10.5281/zenodo.1146566 · Cited by 66
Khanna, S., Sims, M. D., Louie, T., Fischer, M., LaPlante, K. L., Allegretti, J. R., Hasson, B. R., Fonte, A. T., McChalicher, C. W. J., Ege, D. S., et al. (2022) · Antibiotics · doi:10.3390/antibiotics11091234 · Cited by 61
Paquet, J.-C., Claus, S. P., Cordaillat‐Simmons, M., Mazier, W., Rawadi, G., Rinaldi, L., Elustondo, F., & Rouanet, A. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.716266 · Cited by 60
Wang, Y., Wang, X., Cao, X.-Y., Zhu, H., & Miao, L. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1120789 · Cited by 57
EFSA Panel on Dietetic Products, N. A. A. (., Turck, D., Bresson, J., Burlingame, B., Dean, T., Fairweather‐Tait, S., Heinonen, M., Hirsch‐Ernst, K. I., Mangelsdorf, I., McArdle, H. J., et al. (2017) · EFSA Journal · doi:10.2903/j.efsa.2017.4680 · Cited by 49
EFSA Panel on Dietetic Products, N. A. A. (. (2021) · EFSA Journal · doi:10.2903/j.efsa.2021.6554 · Cited by 43
Gueimonde, M., Ouwehand, A. C., & Salminen, S. (2004) · Scandinavian Journal of Nutrition · doi:10.1080/11026480410026447 · Cited by 39
Self-citationLenoir‐Wijnkoop, I., Gerlier, L. C., Bresson, J., Pen, C. L., & Berdeaux, G. (2015) · PLoS ONE · doi:10.1371/journal.pone.0122765 · Cited by 38
Lenoir-Wijnkoop, I., Merenstein, D., Korchagina, D., Broholm, C., Sanders, M. E., & Tancredi, D. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00980 · Cited by 34
Recent systems biology approaches for probiotics use in health aspects: a review
Yadav, M., & Shukla, P. (2019) · 3 Biotech · doi:10.1007/s13205-019-1980-5 · Cited by 31 · cited 1×
“Nevertheless, such challenges may also stimulate creativity and catalyze new approaches (Zeilstra et al., 2018; Yadav and Shukla, 2019; Cunningham et al., 2021; Trukhachev et al., 2021).”
BackgroundLenoir-Wijnkoop, I., Gerlier, L., Roy, D., & Reid, G. (2016) · PLOS ONE · doi:10.1371/journal.pone.0166232 · Cited by 30
Nivoliez, A., Veisseire, P., Alaterre, E., Dausset, C., Baptiste, F., Camarès, O., Gachinat, M., Bonnet, M., Forestier, C., & Bornes, S. (2014) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-014-6110-z · Cited by 28
Probiotics to prevent necrotizing enterocolitis and reduce mortality in neonates: A meta-analysis
Wang, H., Meng, X., Xing, S., Guo, B., Chen, Y., & Pan, Y. (2023) · Medicine · doi:10.1097/md.0000000000032932 · Cited by 28
Leal, J. R., Heitman, S. J., Conly, J. M., Henderson, E. A., & Manns, B. (2016) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2016.134 · Cited by 27
EFSA Panel on Dietetic Products, N. A. A. (. (2021) · EFSA Journal · doi:10.2903/j.efsa.2021.6544 · Cited by 27 · cited 2×
“FSMPs, however, can be manufactured under GMP standards (EFSA, 2021).”
BackgroundProbiotic biomarkers and models upside down: From humans to animals
Trukhachev, V., Chmykhalo, V. K., Belanova, A. A., Beseda, D. K., Chikindas, M. L., Борисовна, Б. А., Ermakov, A. M., Donnik, I. M., Belousova, M. M., & Zolotukhin, P. V. (2021) · Veterinary Microbiology · doi:10.1016/j.vetmic.2021.109156 · Cited by 27
Shen, N. T., Leff, J. A., Schneider, Y., Crawford, C. V., Maw, A., Bosworth, B. P., & Simon, M. S. (2017) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofx148 · Cited by 24
Clinical Trials of Probiotics in Patients With Irritable Bowel Syndrome: Some Points to Consider
Quigley, E. M. M. (2022) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm22012 · Cited by 17 · cited 3×
“However, such biomarkers of risk reduction are minimally established ( Table 2 ) and can be highly challenging to identify for specific health outcomes such as irritable bowel syndrome (IBS) (Quigley, 2022).”
BackgroundMethodInfluentialProbiotics in hospitalized adult patients: a systematic review of economic evaluations
Lau, V. I., Rochwerg, B. N., Xie, F., Johnstone, J., Basmaji, J., Balakumaran, J., Iansavitchene, A., & Cook, D. J. (2019) · Canadian Journal of Anesthesia/Journal canadien d anesthésie · doi:10.1007/s12630-019-01525-2 · Cited by 13
Updated list of QPS-recommended biological agents for safety risk assessments carried out by EFSA
Panel, E. B., Koutsoumanis, K. P., Allende, A., et al. (2022) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.6902983 · Cited by 10
Authenticity of probiotic foods and supplements: Up-to-date situation and methods to assess it
Fusco, V., Fanelli, F., & Chieffi, D. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-89908-6.00015-7 · Cited by 7
van der Geest, A. M., Schukking, I., Brummer, R. J., Pieterse, H., van den Nieuwboer, M., van de Burgwal, L., & Larsen, O. F. A. (2022) · Beneficial Microbes · doi:10.3920/bm2021.0124 · Cited by 4
Research works printed but not linked: 14
- CFI Team (2023). Current Good Manufacturing Practices (CGMPs). Available online at: https://corporatefinanceinstitute.com/resources/valuation/current-good-manufacturing-practices-cgmps/ (accessed October 15, 2023).
- Chieffi D. Fanelli F. Fusco V. (2022). Legislation of probiotic foods and supplements. Probiotics for human nutrition in health and disease. Amsterdam: Elsevier.
- European Commission [EC] (2007). Corrigendum to Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health claims made on foods. Official J. Eur. Union 12: 16.
- HealthEcon (2023). Reimbursement of Pharmaceuticals. Available online at: https://www.healthecon.com/reimbursement/index_eng.html (accessed August 04, 2023).
- Health Canada. (2023). Probiotics. Available online at: https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq.do?atid=probio (accessed December 01, 2023).
- IPA Europe (2023). Do you know what probiotics are? Available online at: https://www.ipaeurope.org/wp-content/uploads/2023/01/202211Survey-report-1.pdf
- Lumina Intelligence (2021). Explained: The US E-commerce probiotic supplements market. Available online at: https://www.lumina-intelligence.com/probiotics-reports/explained-the-us-e-commerce-probiotics-market/ (accessed December 01, 2023).
- Markel Services Inc (2023). Hazard Analysis and Critical Control Points (HACCP) understanding HACCP food safety standards. Available online at: https://www.markelinsurance.com/resources/hazard-analysis-and-critical-control-points (accessed October 15, 2023).
- Paraskevakos G. (2020). Global overview for probiotics: trends, markets, and harmonization. Regulatory Focus. Available online at: https://www.raps.org/news-and-articles/news-articles/2022/9/global-overview-for-probiotics-trends-markets-and#citation (accessed October 15, 2023).
- The European Directorate for the Quality of Medicines and HealthCare [EDQM] (2019). Live biotherapeutic products for human use 3053 monograph. Eur. Pharmacopoeia 9 6522– 6523.
- United States Food and Drug Administration [FDA] (2016). Early clinical trials with live biotherapeutic products: chemistry, manufacturing, and control information. Guidance for Industry. Silver Spring, MD: FDA.
- United States Food and Drug Administration [FDA] (2021). Facts About the Current Good Manufacturing Practices (CGMPs). Silver Spring, MD: FDA.
- United States Food and Drug Administration [FDA] (2022a). Authorized health claims that meet the Significant Scientific Agreement (SSA) Standard. Silver Spring, MD: FDA.
- United States Food and Drug Administration [FDA] (2022b). Investigational New Drug (IND) application. Silver Spring, MD: FDA.
Cited by
Abouelela, M. E., & Helmy, Y. A. (2024) · Microorganisms · doi:10.3390/microorganisms12030430 · Cited by 238
“The situation in the EU is not currently harmonized, with different member states taking different approaches to the regulation of probiotics [47].”
BackgroundEncapsulation method of probiotic embedded delivery system and its application in food
Bu, W., McClements, D. J., Zhang, Z., Zhang, R., Jin, Z., & Chen, L. (2024) · Food Hydrocolloids · doi:10.1016/j.foodhyd.2024.110625 · Cited by 87
Progress in Probiotic Science: Prospects of Functional Probiotic‐Based Foods and Beverages
Manan, M. A. (2025) · International Journal of Food Science · doi:10.1155/ijfo/5567567 · Cited by 91
“Proving the e ffi cacy of these products through scienti fi c evidence and clinical trials is often intricate and time-consuming [18, 314].”
InfluentialRecent advances in prebiotics: Classification, mechanisms, and health applications
Ali, S., Hamayun, M., Siraj, M., Khan, S. A., Kim, H., & Lee, B. (2025) · Future Foods · doi:10.1016/j.fufo.2025.100680 · Cited by 78
Sachdeva, A., Tomar, T., Malik, T., Bains, A., & Karnwal, A. (2025) · Frontiers in Sustainable Food Systems · doi:10.3389/fsufs.2024.1523678 · Cited by 84
Metadata
- Authors
- Spacova, I., Binda, S., ter Haar, J. A., Henoud, S., Legrain-Raspaud, S., Dekker, J., Espadaler-Mazo, J., Langella, P., Martín, R., Pane, M., & Ouwehand, A. C.
- Affiliations
- University of Antwerp (BE)
- Fonterra (New Zealand) (NZ)
- AgroParisTech (FR)
- Probiotical (Italy) (IT)
- Corresponding author
- Spacova, Irina
- Ouwehand, Arthur C.
- Venue
- Frontiers in Microbiology
- Publisher
- Frontiers Media SA
- Published
- 2023-12-19
- Volume
- 14
- Issue
- 3
- Pages
- 1272754-1272754
- ISSN
- 1664-302X (ISSN-L)
- PMC
- PMC10770255
- OpenAlex
- W4389938247
- Cited by
- 129
- References
- 50
- Citations by year
- 2026: 68 · 2025: 47 · 2024: 14
- FWCI
- 2.98
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Microbiology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion, cc-by-nd)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Fonds Wetenschappelijk Onderzoek (1277222N)
- Vlaamse regering
- Topics
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Life Sciences › Agricultural and Biological Sciences › Food Science › Agricultural safety and regulations
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Consumer Attitudes and Food Labeling
- Keywords
- probiotics, probiotic foods, live biotherapeutic products, probiotic regulation, regulatory guidelines, product development, clinical research, health claims, commercialization
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.